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Abstract
The release of 5-HT in terminal areas of the rodent brain is
regulated by 5-HT1B receptors. Here we examined the role of
5-HT1B receptors in the control of 5-HT output and ®ring in the
dorsal raphe nucleus (DR), median raphe nucleus (MnR) and
forebrain of the rat in vivo. The local perfusion (30±300 mM) of
the selective 5-HT1B receptor agonist CP-93,129 to freely
moving rats decreased 5-HT release in the DR and more
markedly in the MnR. Likewise, 300 mM CP-93,129 reduced
5-HT output in substantia nigra pars reticulata, ventral
pallidum, lateral habenula and the suprachiasmatic nucleus.
The effect of CP-93,129 was prevented by SB-224289, but
not by WAY-100635, selective 5-HT1B and 5-HT1A receptor
antagonists, respectively. SB-224289 did not alter dialysate
5-HT in any raphe nuclei. The intravenous administration of the
brain-penetrant selective 5-HT1B receptor agonist CP-94,253
(0.5±2.0 mg/kg) to anesthetized rats decreased dialysate
5-HT in dorsal hippocampus and globus pallidus, increased it
in MnR and left it unaltered in the DR and medial prefrontal
cortex. SB-224289, at a dose known to block 5-HT1B
autoreceptor-mediated effects (5 mg/kg), did not prevent the
effect of CP-94,253 on MnR 5-HT. The intravenous adminis-
tration of CP-94,253 (0.05±1.6 mg/kg) to anesthetized rats
increased the ®ring rate of MnR, but not DR-5-HT neurons.
The local perfusion of CP-94,253 in the MnR showed a
biphasic effect, with 5-HT reductions at 0.3±3 mM and
increase at 300 mM. These results suggest that 5-HT cell
®ring and release in midbrain raphe nuclei (particularly in the
MnR) are under control of 5-HT1B receptors. The activation
of 5-HT1B autoreceptors (possibly located on 5-HT nerve
endings and/or varicosities within DR and MnR) reduces 5-HT
release. The effects of higher concentrations of 5-HT1B
receptor agonists seem more compatible with the activation
of 5-HT1B heteroreceptors on inhibitory neurons.
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The release of serotonin (5-hydroxytryptamine, 5-HT) in
nerve endings is regulated by somatodendritic 5-HT1A and
terminal 5-HT1B/1D receptors. The stimulation of 5-HT1A
receptors in the midbrain dorsal (DR) or median (MnR)
raphe nucleus suppresses ®ring of serotonergic cells
(Sprouse and Aghajanian 1986, 1987; VanderMaelen et al.
1986; Sinton and Fallon 1988) and release of 5-HT in
terminal areas of the brain (Hutson et al. 1989; Sharp et al.
1989a; Bonvento et al. 1992; Adell et al. 1993; Bosker et al.
1994; Kreiss and Lucki 1994; Casanovas et al. 1997).
Several studies in vivo have shown that 5-HT1B/1D receptor
agonists reduce 5-HT release in nerve endings (Sharp et al.
1989b; Hjorth and Tao 1991; Roberts et al. 1997, 2000;
Gaster et al. 1998; Hertel et al. 1999; Knobelman et al.
2000). There is also evidence that indicates the presence of
5-HT1B and 5-HT1D receptors in the DR whose activation
decreases the local release of 5-HT (Starkey and Skingle
1994; Davidson and Stamford 1995; PinÄeyro et al. 1995;
Moret and Briley 1997). The role that 5-HT1B receptors play
in the control of serotonergic cell ®ring is more contro-
versial. Thus, initial observations showed that 5-HT1B/1D
receptor agonists failed to alter spontaneous 5-HT cell ®ring
in the DR (Sprouse and Aghajanian 1986, 1987; PinÄeyro
et al. 1996; Sprouse et al. 1997). This led to the conclusion
that 5-HT1B receptors are not involved in the regulation of
5-HT neuron ®ring activity. Nevertheless, other work has
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described that higher doses of 5-HT1B receptor agonists
enhanced 5-HT cell ®ring in the DR (Evrard et al. 1999;
Hertel et al. 2001) and the MnR (Sinton and Fallon
1988), although this effect has not been characterized
pharmacologically.
Besides its role as an autoreceptor that regulates the
release of 5-HT, the 5-HT1B subtype has also been described
as heteroreceptor located on non-serotonergic terminals of
the brain where it controls the release of other neuro-
transmitters such as glutamate (Boeijinga and Boddeke
1993; Tanaka and North 1993; Li and Bayliss 1998), GABA
(Stanford and Lacey 1996; Chadha et al. 2000), acetyl-
choline (Maura and Raiteri 1986; BolanÄos-JimeÂnez et al.
1994) and dopamine (Sarhan et al. 1999), among others.
Consistent with the notion that 5-HT1B receptors exist as
auto- or heteroreceptors to regulate the release of
neurotransmitters, they have been visualized predomi-
nantly in nerve terminals or pre-terminal axons (Boschert
et al. 1994; Sari et al. 1997, 1999; Riad et al. 2000).
In contrast, a high density of 5-HT1B receptor mRNA
has been detected in the raphe nuclei of the rat (Voigt
et al. 1991; Bruinvels et al. 1994; Doucet et al.
1995).
Until recently it has been impossible to discriminate
pharmacologically between 5-HT1B and 5-HT1D receptors
because of the lack of selective compounds. At present, a
few 5-HT receptor agonists such as CP-93,129 (Macor et al.
1990; Koe et al. 1992a,b) and CP-94,253 (Koe et al. 1992c)
have been shown to display high af®nity and a good
selectivity for the 5-HT1B subtype. In addition, some
selective 5-HT1B receptor antagonists such as SB-224289
(Gaster et al. 1998; Roberts et al. 1998) have been
developed.
In the present study we assessed the role of 5-HT1B
receptors in the control of 5-HT release and 5-HT cell ®ring
in the rat brain. Speci®cally, we examined the effects of the
local application of the selective 5-HT1B receptor agonists
CP-93,129 on the 5-HT output in the DR, MnR and various
projection areas of both nuclei in the forebrain. In the second
part of the study we examined the role of 5-HT1B receptors
in the control of serotonergic cell ®ring in the DR and MnR.
Given that CP-93,129 does not cross the blood±brain
barrier, we used its propoxy derivative CP-94,253, which
is a selective and brain-penetrant 5-HT1B receptor agonist
and therefore can be administered systemically. Finally,
we examined whether or not electrophysiological changes
paralleled changes in 5-HT release. For this purpose
CP-94,253 was administered intravenously to chloral
hydrate anesthetized rats and 5-HT ef¯ux was measured
in both raphe nuclei and three projection areas of the
forebrain. A preliminary account of some of the ®ndings
of the present study was presented to the 30th Annual
Meeting of the Society for Neuroscience (Adell et al.
2000).
Materials and methods
Animals
Male Wistar rats weighing 280±350 g were supplied by Iffa-Credo
(Lyon, France). The rats were group housed in a room controlled
for temperature (22 ^ 28C) and a 12-h lighting cycle (lights on at
07 : 00). Food and water were available ad libitum. All experi-
mental procedures were approved by the local Institutional Animal
Care and Use Committee and conducted in strict compliance with
the European Communities Council Directive on `Protection of
Animals Used in Experimental and Other Scienti®c Purposes' of 24
November 1986 (86/609/EEC). All efforts were made to minimize
animal suffering and to reduce the number of animals used.
Chemicals and drugs
All the reagents were of analytical grade and obtained from Merck
(Darmstadt, Germany). The 5-HT1B receptor agonist CP-93,129
was purchased from Tocris Cookson Ltd (Bristol, UK). The 5-HT1A
receptor agonist 8-OH-DPAT and the 5-HT1A receptor antagonist
WAY-100635 were from RBI (Natick, MA, USA). Citalopram
hydrobromide, the 5-HT1B receptor agonist CP-94,253 and the
5-HT1B receptor antagonist SB-224289 were generously donated by
H. Lundbeck A/S (Copenhagen-Valby, Denmark), P®zer (Groton,
CT, USA) and SmithKline Beecham Pharmaceuticals (Harlow,
Essex, UK), respectively. For local administration through dialysis
probes, each of the drugs was dissolved in arti®cial CSF.
Concentrated solutions were stored at 2808C, and working
solutions were prepared immediately before the experiments. For
systemic administration drugs were dissolved in saline, except for
SB-224289, which was suspended in 1% sucrose and gently
warmed. All the doses administered are referred as free base.
Groups of rats were perfused with arti®cial CSF or injected with
vehicle to serve as control for the local or systemic administration
of drugs.
Intracerebral microdialysis
Procedures of microdialysis probe construction were described
previously (Adell and Artigas 1998). Concentrically designed
probes were made up of a 25-gauge stainless steel cannula (A-M
Systems, Carlsborg, WA, USA) into which a capillary fused silica
tube (Polymicro Technologies, Phoenix, AZ, USA) was inserted.
Dialysis membranes of 5000 Da molecular weight cut-off were
made from hollow cuprophan ®bers (252 mm outer diameter). On
the day preceding dialysis experiment, rats were anesthetized with
an i.p. injection of 60 mg/kg sodium pentobarbital and placed in a
stereotaxic frame (David Kopf, Tujunga, CA, USA). Microdialysis
probes with a 1.5-mm-long exchange surface were implanted using
the following coordinates (in mm) from bregma and the top of the
skull, according to Paxinos and Watson (1986): DR (AP 27.8, L
23.1, DV 27.7, with a lateral angle of 308), MnR (AP 27.8, L
22.0, DV 29.3, with a lateral angle of 138), dorsal hippocampus
(AP 22.0, L 1 1.2, DV 24.2), medial pre-frontal cortex (mPFC,
AP 1 3.0, L 1 0.5, DV 25.5), globus pallidus (AP 21.4, L 23.2,
DV 27.4), substantia nigra pars reticulata (AP 25.2, L 1 2.4, DV
28.8), lateral habenula (AP 23.8, L 20.6, DV 25.4), ventral
pallidum (AP 1 0.2, L 21.8, DV 29.0), and suprachiasmatic
nucleus (AP 21.0, 2 0.3, DV 29.6). Microdialysis was performed
24 h after surgery in freely moving rats by continuously perfusing
probes with ®ltered arti®cial CSF containing 125 mm NaCl,
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2.5 mm KCl, 1.18 mm MgCl2, 1.26 mm CaCl2, and 1 mm
citalopram. The arti®cial CSF was perfused at a ¯ow rate of
0.25 mL/min with a Harvard model 22 syringe pump (Harvard
Apparatus, South Natick, MA, USA) attached to an overhead liquid
swivel (Instech, Plymouth Meeting, PA, USA). Dialysate samples
of 5 mL were collected at 20-min intervals into microcentrifuge
vials. After an initial 1 h sample of dialysate was discarded, four
samples were collected to establish stable baseline levels of 5-HT.
In some experiments microdialysis was carried out in anesthetized
animals. For this purpose dialysis probes were implanted as
described above and 24-h later animals were anesthetized with
chloral hydrate (400 mg/kg, i.p.) and supplemental doses were
injected to maintain anesthesia throughout the experiment. At the
completion of dialysis experiments, rats were given an overdose of
sodium pentobarbital and a fast green solution was perfused
through the dialysis probes to stain the surrounding tissue. The
brain was removed, frozen, and sliced free hand at the appropriate
levels using a surgical blade. Data were excluded if the probe track
was not in the targeted site.
Biochemical measurements
Dialysate samples were analyzed for 5-HT by a HPLC method
described previously (Adell and Artigas 1998). Brie¯y, 5-HT
was separated on a 3-mm octadecylsilica (ODS) column
(7.5 cm  0.46 cm; Beckman, San Ramon, CA, USA) and
detected amperometrically with a Hewlett-Packard 1049 detector
(Palo Alto, CA, USA) set at an oxidation potential of 0.6 V. The
detection limit for 5-HT was estimated to be around 1 fmol/sample.
Quanti®cation of 5-HT was carried out by an external standard
method using a Nelson Turbochrom Navigator (Perkin-Elmer, San
Jose, CA, USA).
Single unit recordings
Single unit extracellular recordings were performed as previously
described (Sawyer et al. 1985; Celada et al. 1996). Rats were
anesthetized with chloral hydrate (400 mg/kg, i.p.) and the femoral
vein was cannulated to administer drugs and additional anesthetic
(chloral hydrate, 80 mg/kg) when needed. The animals were then
placed in a stereotaxic frame. All wound margins and points of
contact between the animal and the stereotaxic apparatus were
impregnated with a 5% lidocaine solution. Body temperature was
maintained at 37 ^ 18C with a heating pad. The atlanto-occipital
membrane was punctured to allow drainage of the CSF. A
4  4 mm recording hole was drilled over the lambda and the
sagittal sinus was ligated, cut and re¯ected.
Recording electrodes were fabricated from 2.0 mm outer
diameter capillary glass (WPI, Saratosa, FL, USA) pulled on a
Narishige PE-2 pipette puller (Narishige Scienti®c Instruments,
Tokyo, Japan) and ®lled with 2 m NaCl and few crystals of
pontamine sky blue. The electrode impedance was lowered
between 4 and 10 MV by passing 500 ms 150 V DC pulses
through the electrode (Grass Stimulation Model S-48).
Single unit extracellular recordings were ampli®ed with a
Neurodata IR283 (Cygnus Technology Inc., Delaware Water
Gap, PA, USA), post-ampli®ed and ®ltered with a Cibertec
ampli®er (Madrid, Spain) and computed on-line through a DAT
1401plus interface system using Spike2 software (Cambridge
Electronic Design, Cambridge, UK). Data were also recorded on
magnetic audiotape for off-line recording if necessary.
Descents were carried out along the midline and 5-HT neurons
were recorded at 5.90 ^ 0.25 mm (DR) and 8.33 ^ 0.23 mm
(MnR) below the brain surface. Serotonergic neurons were
identi®ed according to previously described electrophysiological
criteria (Wang and Aghajanian 1977, 1982). They exhibited a
regular ®ring rate with frequencies of 0.3±3.2 Hz, and 2±5 ms bi-
or triphasic extracellular waveform. After recording stable baseline
spontaneous activity for at least 5 min, CP-94,253 was adminis-
tered i.v. at increasing doses every minute. The selective 5-HT1A
receptor agonist 8-OH-DPAT was injected at the end of experi-
ments to further verify the serotonergic nature of recorded neurons.
Experiments were ®nalized by passing current through the
electrode to leave a blue spot at the recording site. Recordings
were made from one cell in each animal. At the end of each
experiment rats were given a lethal overdose of anesthetic and
perfused with 10% buffered formalin. Brains were removed,
sectioned and stained with Neutral Red for histological veri®cation
of the recording sites.
Data analysis
Unless otherwise speci®ed, results are expressed as mean ^SEM.
In dialysis experiments, the average of four fractions before drug
administration was de®ned as 100% (baseline), and the subsequent
perfusate levels were expressed as a percentage of the pre-treatment
baseline level. These values as well as electrophysiological data
were analyzed with a one- or two-way repeated measures anova
followed by the Duncan's multiple range test. For all procedures
the level of signi®cance was set at p , 0.05. All statistical
procedures were performed using the Statistica software for
Windows (StatSoft, Tulsa, OK, USA).
Results
Basal values of dialysate 5-HT in the raphe nuclei
In freely moving awake animals the basal values of 5-HT in
dialysate samples of DR and MnR in the presence of 1 mm
citalopram were 23.9 ^ 3.0 fmol/5 mL (n  26) and
33.8 ^ 3.0 fmol/5 mL (n  47), respectively. The output
of 5-HT in the MnR was signi®cantly higher than that in the
DR ( p , 0.05, t-test). In chloral hydrate-anesthetized
animals the basal values of 5-HT in dialysate samples of
DR and MnR in the presence of 1 mm citalopram were
14.0 ^ 1.3 fmol/5 mL (n  9) and 18.4 ^ 2.0 fmol/5 mL
(n  16), respectively. In both raphe nuclei the output of
5-HT was higher in awake compared to anesthetized
animals. However, in the DR this difference did not reach
statistical signi®cance.
Effects of CP-93,129 on dialysate 5-HT
The compound CP-93,129 exhibits a high af®nity for the
5-HT1B receptor (Ki  8.1 nm; Koe et al. 1992a,b,c) with
greater that 100-fold binding selectivity over 5-HT1D sites
(Ki  1100 nm; Koe et al. 1992a,b,c). The effects of the
local perfusion of CP-93,129 on dialysate 5-HT in DR and
MnR of awake animals are depicted in Fig. 1. In the DR,
anova analysis revealed signi®cant effects of concentration
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of CP-93,129 ( p , 0.05), time ( p , 0.001) and the inter-
action between both factors ( p , 0.001). Post-hoc compari-
sons showed that 100 mm and 300 mm of the 5-HT1B agonist
decreased extracellular 5-HT to a similar extent, i.e. ,60%
of control values at the offset of perfusion. In the MnR,
anova analysis revealed signi®cant effects of concentration
of CP-93,129 ( p , 0.001), time ( p , 0.001) and the inter-
action between both factors ( p , 0.001). Post-hoc compari-
sons showed that 30 mm CP-93,129 decreased dialysate
5-HT to a ,70% whereas at 100 mm and 300 mm, this
compound evoked a maximal reduction of dialysate 5-HT to
a ,30% of control values. Overall, the reduction in 5-HT
release following CP-93,129 was signi®cantly more marked
in the MnR compared to the DR ( p , 0.05). The continuous
perfusion of arti®cial CSF throughout the experiment did not
modify the release of 5-HT in both raphe nuclei. To rule out
the participation of 5-HT1A receptors in the decrease of the
5-HT release induced by CP-93,129, the 5-HT1A antagonist
WAY-100635 (Fletcher et al. 1995; Forster et al. 1995) was
perfused simultaneously with CP-93,129. WAY-100635,
at the concentration of 100 mm, which antagonizes the
decrease in 5-HT release produced by 8-OH-DPAT in the
MnR (Adell and Artigas 1998), did not affect 5-HT release
per se and failed to alter CP-93,129-induced reduction of
5-HT release in the MnR (Fig. 2).
In order to compare the effects of CP-93,129 in the
raphe nuclei and several projection areas, this compound
was perfused locally in areas known to be connected
with the raphe nuclei, i.e. the lateral habenula and the
Fig. 2 Effects of the simultaneous perfusion of CP-93,129 (CP) and
WAY-100635 (WAY) on the dialysate 5-HT in the MnR. Each bar is
the mean ^SEM of the number of animals indicated in parentheses.
Each compound or combination was perfused during 100 min (5 dia-
lysate samples) and the 5-HT release responses were averaged
over the last three samples and expressed as the percentage
change from the control group (open bar). *Signi®cantly different
from control group ( p , 0.05), Duncan's multiple range test.
Fig. 3 Effect of the local perfusion of 300 mM CP-93,129 in sub-
stantia nigra pars reticulata (O, SN reticulata, n  4), ventral pal-
lidum (X, n  2), lateral habenula (A, n  4) and the
suprachiasmatic nucleus (L, n  2). Results are expressed as the
mean ^SEM of the percentage changes from pre-drug values.
CP-93,129 signi®cantly reduced dialysate 5-HT in the four projection
areas studied ( p , 0.001).
Fig. 1 Effect of the local perfusion of arti®cial CSF (Control) or
CP-93,129 in DR (a) and MnR (b). Results are expressed in
percentage changes from pre-drug values and each point is the
mean ^SEM of 4±6 rats. In comparison with the control group
CP-93,129 decreased dialysate 5-HT signi®cantly at the concen-
trations of 100 mM and 300 mM ( p , 0.05) in the DR and 30 mM
( p , 0.05), 100 mM and 300 mM ( p , 0.01) in the MnR.
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suprachiasmatic nucleus (Aghajanian and Wang 1977;
Moore et al. 1978) and also enriched in 5-HT1B receptors
such as substantia nigra pars reticulata and ventral pallidum
(Sari et al. 1999). As shown in Fig. 3, the local perfusion of
300 mm CP-93,129 signi®cantly reduced dialysate 5-HT in
the four projection areas studied ( p , 0.001) to a similar
extent (,35±45% of pre-drug values), which was not sig-
ni®cantly different from the effect of the same concentration
in the MnR.
Fig. 4 Effect of the local perfusion of arti®cial CSF (Control) or
increasing concentrations of SB-224289 on the output of 5-HT in the
DR (a) and MnR (b). Results are expressed in percentage changes
from pre-drug values and each point is the mean ^SEM of 5±7
rats. The 5-HT1B antagonist SB-224289 did not modify dialysate
5-HT in any of the midbrain raphe nuclei. (a) A, control; B,
SB-224289. (b) X, control; W, SB-224289.
Fig. 5 Effects of the simultaneous perfusion of CP-93,129 (CP) and
SB-224289 (SB) on the dialysate 5-HT in the MnR. Results
expressed as the mean ^SEM of the number of animals indicated
in parentheses. Each compound or combination was perfused during
100 min (5 dialysate samples) and the 5-HT release responses were
averaged over the last three samples and expressed as the percent-
age change from the control group. *Signi®cantly different from
control group ( p , 0.05), Duncan's multiple range test.
Fig. 6 Effects of intravenous administration of CP-94,253 on the
spontaneous ®ring rate of two representative 5-HT neurons from DR
(a) and MnR (b). The doses injected in arrows were 0.05, 0.05, 0.1,
0.2, 0.4 and 0.8 mg/kg. An additional dose of 1.6 mg/kg CP-94,253
was injected when 5-HT neurons were recorded in the MnR. 5-HT
neuron in (a) was inhibited by 0.5, 0.5, 1.0 and 2.0 and that in (b) by
2.0 and 2.0 mg/kg 8-OH-DPAT (i.v.). Also depicted is the effect of
cumulative doses of CP-94,253 on the ®ring rate of serotonergic
neurons in the DR and MnR (c). Each point represents the
mean ^ SEM of 6±8 cells and is expressed in percentage changes
from pre-drug values. *Signi®cantly different from basal values
( p , 0.05), Duncan's multiple range test.
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Effects of local SB-224289 and CP-93,129 on dialysate
5-HT
The effects of cumulative concentrations of SB-224289 on
dialysate 5-HT in DR and MnR of awake animals are shown
in Fig. 4. At the concentrations tested (1±100 mm) this
5-HT1B antagonist had no effect on extracellular 5-HT in
both nuclei. However, SB-224289 blocked the decrease in
5-HT release in the MnR evoked by CP-93,129 in a
concentration-dependent manner ( p , 0.01). Thus, although
100 mm SB-224289 was not suf®cient to block the effect of
50 mm CP-93,129, 200 mm of SB-224289 (which alone did
not alter dialysate 5-HT) was able to prevent the effect of
30 mm of CP-93,129 in reducing dialysate 5-HT in the MnR
(Fig. 5).
Effects of CP-94,253 on 5-HT cell ®ring
The compound CP-94,253 exhibits a high af®nity for the
5-HT1B receptor (Ki  2.0 nm; Koe et al. 1992c) with
25-fold greater binding selectivity over 5-HT1D sites
(Ki  49 nm; Koe et al. 1992c). The basal ®ring rate of
5-HT cells recorded was 1.2 ^ 0.3 spikes/s in the DR
(n  8) and 0.7 ^ 0.2 spikes/s in the MnR (n  7). The
effects of cumulative doses of CP-94,253 on the ®ring of
two 5-HT neurons in the DR and MnR are shown in Fig. 6.
Overall, the systemic administration of cumulative doses of
CP-94,253 (0.05±1.6 mg/kg, i.v.) to chloral hydrate anes-
thetized rats did not change the ®ring activity of DR 5-HT
neurons. In contrast, the same treatment increased signi®-
cantly ( p , 0.001) the ®ring rate of 5-HT neurons in the
MnR. Post hoc comparisons showed that the effects of
cumulative doses 0.2±1.6 mg/kg of CP-94,253 were
statistically signi®cant.
The administration of vehicle (0.9% NaCl) did not alter
the spontaneous ®ring activity of 5-HT neurons in any of the
raphe nuclei (data not shown).
Effects of CP-94,253 on dialysate 5-HT
The effects of the systemic administration of CP-94,253 on
dialysate 5-HT in the raphe nuclei and three projection areas
of chloral hydrate anesthetized rats are depicted in Fig. 7.
anova analysis revealed signi®cant effects of brain region
( p , 0.01), time ( p , 0.001) and the interaction between
both factors ( p , 0.001). When comparisons were estab-
lished between the corresponding control groups in each
region (not shown), anova analysis revealed signi®cant
Fig. 7 Effects of the intravenous administration of CP-94,253
(arrows) to chloral hydrate anesthetized rats on dialysate 5-HT in
DR (W, n  5), MnR (A, n  4), medial pre-frontal cortex (X, mPFC;
n  5), dorsal hippocampus (P, DHPC; n  5) and globus pallidus
(B, GP, n  4). For each region a control group (n  4±5) was run
in which the rats were injected intravenously with saline (not shown).
Results are mean ^SEM and expressed in percentage changes
from pre-drug values. The effects of CP-94,253 were signi®cant in
MnR, dorsal hippocampus and globus pallidus ( p , 0.01) but not in
DR and mPFC.
Fig. 8 Effect of the local perfusion of arti®cial CSF (Control,
n  5±7) or different concentrations of CP-94,253 (n  5±7) on the
output of 5-HT in the MnR. Arti®cial CSF or different concentrations
of CP-94,253 were perfused during 100 min (5 dialysate samples)
and the 5-HT release responses were averaged over the last three
samples and expressed as the percentage change from the control
group. Signi®cant differences from respective control groups:
* p , 0.001, ** p , 0.01 and *** p , 0.02, paired Student's t-test.
Fig. 9 Effects of the simultaneous perfusion of CP-94,253 (CP) and
SB-224289 (SB) on the dialysate 5-HT in the MnR. Results
expressed as the mean ^SEM of the number of animals indicated
in parentheses. Each compound or combination was perfused during
100 min (5 dialysate samples) and the 5-HT release responses were
averaged over the last three samples and expressed as the per-
centage change from the control group. *Signi®cantly different from
control group ( p , 0.01), Duncan's multiple range test.
5-HT1B receptors and 5-HT release 177
q 2001 International Society for Neurochemistry, Journal of Neurochemistry, 79, 172±182
effects of treatment in MnR, dorsal hippocampus and globus
pallidus ( p , 0.01), but not in DR and mPFC. The decrease
in dialysate 5-HT induced by CP-94,253 was already
signi®cant following the injection of 1.0 mg/kg in the
globus pallidus ( p , 0.01), but only after the injection of
2.0 mg/kg in the dorsal hippocampus ( p , 0.01).
Effects of SB-224289 and CP-94,253 on dialysate 5-HT
In order to compare the local effects of CP-93,129 and
CP-94,253 in the MnR, a wide range of concentrations of the
latter compound (from 30 nm to 300 mm) were perfused
through the dialysis probe in the MnR. The results depicted
in Fig. 8 show a biphasic effect. Lower concentrations
of 300 nm and 3 mm decreased dialysate 5-HT to 74%
( p , 0.01) and 52% ( p , 0.001) of control values, respect-
ively, whereas that of 300 mm increased 5-HT to a 188%
( p , 0.05) of control values. In addition, it was intended to
ascertain whether the decrease of 5-HT in the MnR induced
by lower concentrations of CP-94,253 was due to an action
upon 5-HT1B receptor. For this purpose SB-224289 was
perfused simultaneously with CP-94,253. The concentration
of 200 mm SB-224289 did not alter 5-HT release per se, but
prevented the effect of 3 mm CP-94,253 (Fig. 9).
Finally, to determine whether the increase in 5-HT release
evoked by the intravenous injection of CP-94,253 resulted
from an action upon 5-HT1B autoreceptors, SB-224289
(5 mg/kg, i.v.) was injected 80 min before CP-94,253
(2 mg/kg, i.v.). The results depicted in Fig. 10 show that,
with respect to the control group, 5-HT increased 53%
( p , 0.05) after CP-94,253 and 71% after the combined
treatment ( p , 0.001). The systemic injection of SB-224289
also produced a 33% increase of 5-HT over basal values, but
this did not reach statistical signi®cance.
Discussion
Previous work has suggested the presence of operational
5-HT1B receptors in the DR of the rat (Davidson and
Stamford 1995; HervaÂs et al. 1998; Stamford et al. 2000;
Hertel et al. 2001). However, until recently, the lack of
selective compounds has hampered functional studies on
5-HT1B receptors. To the best of our knowledge, this is the
®rst study in which the highest selective 5-HT1B receptor
agonists and antagonist available are used to compare in vivo
the role of 5-HT1B receptors in the control of 5-HT cell
®ring and release in the DR and MnR of the rat.
The local perfusion of the selective 5-HT1B agonist
CP-93,129 decreased dialysate 5-HT in the DR and MnR of
the rat in a concentration-dependent manner. This agrees
with other studies in the raphe nuclei (Davidson and
Stamford 1995; Moret and Briley 1997; Hertel et al. 2001)
and is coincident to what occurs in projection areas of the
forebrain (Sharp et al. 1989b; Hjorth and Tao 1991; Hertel
et al. 1999; Knobelman et al. 2000). The ®nding that the
reduction in 5-HT release evoked by CP-93,129 is prevented
by concomitant perfusion with SB-224289, but not by
WAY-100635, further strengthens an action upon intraraphe
5-HT1B receptors as observed by others (Davidson and
Stamford 1995). The lower effect of CP-93,129 in the DR
compared to the MnR might be accounted for by different
ef®cacy and/or density of 5-HT1B receptors in each nucleus.
Previous studies have shown that the 5-HT output in the
DR is controlled by 5-HT1D rather than 5-HT1B receptors
(Davidson and Stamford 1995; PinÄeyro et al. 1995, 1996;
Hertel et al. 2001). We agree inasmuch as the effects of
CP-93,129 in the DR are relatively smaller than those in the
MnR. However, in concordance with the present study,
Hopwood and Stamford (2001) have shown recently that the
reduction of 5-HT output in the MnR is not prevented by the
selective 5-HT1D receptor antagonist BRL 15572. It there-
fore seems that 5-HT1B receptors are more important in
regulating 5-HT release in the MnR, whereas the role of
5-HT1D receptors would be more relevant in the DR. The
question remains as to the subcellular localization of these
receptors. As rightly pointed out by Stamford et al. (2000), it
cannot be assumed that a functional action upon a 5-HT
receptor in the raphe nuclei implies a somatodendritic loca-
tion of the receptor. Immunocytochemical studies have
revealed the presence of not only cell bodies and dendrites
in the raphe region, but also an intricate meshwork of 5-HT
®bers (Steinbusch 1981). Furthermore, although less abun-
dant than in forebrain areas, in the raphe region a 40% of
5-HT varicosities and/or terminals has been found (Tao-
Cheng and Zhou 1999) and the 5-HT1B receptor has been
predominantly described in 5-HT terminals (Boschert et al.
Fig. 10 Effects of the intravenous administration of 2 mg/kg
CP-94,253 (CP), 5 mg/kg SB-224289 (SB) or the combination
(SB 1 CP) to chloral hydrate anesthetized rats on dialysate 5-HT
in MnR. Results expressed as the mean ^SEM of the number of
animals indicated in parentheses. When combined, SB was injected
80 min before CP and perfusion continued for 80 more minutes.
The 5-HT release responses were averaged over the last three
samples and expressed as the percentage change from the control
(CTRL) group. Signi®cant differences from control group: * p , 0.05
and ** p , 0.001, Duncan's multiple range test.
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1994; Sari et al. 1999). On the other hand, because the
concentration of 5-HT1B receptor mRNA is similar in both
nuclei (Doucet et al. 1995), our results also suggest that
the receptor protein is less expressed in the DR. Some
immunocytochemical studies have questioned the presence
of the 5-HT1B receptor protein in the raphe nuclei of the
rodent brain (Boschert et al. 1994; Sari et al. 1997, 1999).
However, a limitation of immunocytochemical techniques is
the accessibility of receptor antigenic sites in the plasma
membrane and it is possible that the low amount of 5-HT1B
receptors located in the raphe nuclei (albeit entirely func-
tional) is below the detection limit of the technique. The
decrease in dialysate 5-HT induced by CP-93,129 was
similar in the four projection areas studied and akin to what
the same concentration of the compound produced in the
MnR. Taking into consideration that the amount of 5-HT1B
receptors in those regions are very different (Bruinvels et al.
1993), it would appear that the release of 5-HT in terminal
areas does not depend on the density of such receptors.
However, it must be kept in mind that the majority of the
5-HT1B receptor labeling in the substantia nigra pars
reticulata and ventral pallidum does not correspond to the
autoreceptor but to heteroreceptor in terminals of GABA-
containing neurons (Boschert et al. 1994; Sari et al. 1999).
Therefore, this means that the effects of CP-93,129 observed
are brought about by a small proportion on 5-HT1B sites
located in 5-HT nerve endings. In contrast to the effects of
CP-93,129, the local administration of the selective 5-HT1B
receptor antagonist SB-224289 did not affect dialysate 5-HT
in both raphe nuclei. This suggests that endogenous 5-HT
does not exert a tonic action on 5-HT1B autoreceptors in DR
and MnR, at least in the conditions of the present study. A
lack of effect of SB-224289 on 5-HT release has also been
observed in several regions of the brain of rat (Gobert et al.
2000; HervaÂs et al. 2000) and guinea pig (Roberts et al.
1998). Nevertheless, in the latter work SB-224289 has been
described as an inverse agonist in the dentate gyrus of the
guinea pig because it increases the output of 5-HT (Roberts
et al. 1998). It thus seems that the increase in 5-HT release
evoked by a 5-HT1B receptor antagonist might depend on
the species and the brain region (Barnes and Sharp 1999).
Unlike CP-93,129 (Macor et al. 1990), its propoxy
derivative CP-94,253 enters readily the brain after systemic
administration and thus it could be given intravenously to
study the role of 5-HT1B receptors on 5-HT cell ®ring.
Although the pharmacological pro®le of both compounds is
similar, the af®nity of CP-94,253 for 5-HT1B receptors is
4-fold higher than that of CP-93,129 (Koe et al. 1992c). The
systemic administration of CP-94,253 increased the ®ring
rate of 5-HT cells in the MnR, but not in the DR up to a
cumulative dose of 1.6 mg/kg. This is consistent with
previous studies showing that higher doses of non-selective
5-HT1B receptor agonists increase the discharge rate of
5-HT neurons in the MnR without altering that in the DR of
the rat (Sprouse and Aghajanian 1987; Sinton and Fallon
1988). A recent work also showed that a single 3 mg/kg
dose of CP-94,253 enhances 5-HT cell ®ring in the DR of
mice and that this effect is prevented in 5-HT1B receptor
knock-out mice (Evrard et al. 1999), which clearly suggests
an action upon 5-HT1B receptors. It is conceivable that
higher doses of the compound than those given in the
present work could induce the same effect in the DR of the
rat, although species differences might exist. In our present
study the increase in the electrophysiological activity of
MnR 5-HT neurons parallels the enhanced dialysate 5-HT
found in this nucleus. The presence of citalopram in the
dialysate precludes a direct comparison between data from
microdialysis and single unit recordings. However, it has
been indicated that, at low concentration of citalopram in the
perfusion ¯uid, 5-HT release remains predominantly depen-
dent on depolarization (Tao et al. 2000). It is thus possible
that the increased 5-HT release observed in the present
conditions results from enhanced serotonergic cell ®ring. To
discern whether the increased 5-HT in the MnR after
systemic CP-94,253 was due to an action on 5-HT1B
receptors located within the nucleus or elsewhere, two
additional experiments were conducted. First, the compound
was perfused through a dialysis probe implanted in the MnR
of awake animals. In the lower concentration range (up to
3 mm) CP-94,253 reduced dialysate 5-HT and this effect is
blocked by SB-224289, which indicates an activation of
local 5-HT1B autoreceptors, in line with the effects of
CP-93,129. In contrast, higher concentrations of CP-94,253
increased 5-HT as observed following systemic administra-
tion. Secondly, systemic SB-224289, at a dose known to
block 5-HT1B autoreceptor-mediated effects (Gaster et al.
1998), failed to prevent the CP-94,253-induced increase in
5-HT release. Thus, the question remains as to whether or
not the effect of systemic CP-94,253 on MnR 5-HT is due to
its agonism on 5-HT1B receptors. Previous work with
5-HT1B receptor knock-out mice attributed the CP-94,253-
induced elevation of 5-HT cell ®ring to an action upon
5-HT1B receptors located outside the raphe which would
activate a distal feedback loop (Evrard et al. 1999). It is
conceivable that this also caused the elevated 5-HT in the
MnR in the present study. The negligible af®nity of
CP-94,253 for other transmitter receptors (Koe et al.
1992c) nearly precludes an unspeci®c action of the
compound. The biphasic effect of local CP-94,253 rather
suggests actions on different populations of 5-HT1B recep-
tors. Without ruling out the distal loop alternative, we
hypothesize that the increase of 5-HT release (and possibly
serotonergic ®ring rate) in the MnR might also be mediated
by 5-HT1B heteroreceptors located in inhibitory neurons
impinging upon 5-HT cells. In good accordance with this
hypothesis, it has been observed that the sensitivity of
5-HT1B receptor agonists and antagonists for the 5-HT1B
autoreceptor is ,90 fold higher than that for the
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heteroreceptor counterpart (Sarhan and Fillion 1999).
Needless to say that further investigation is needed to
authenticate this hypothesis.
The systemic administration of CP-94,253 reduced
dialysate 5-HT in terminal areas as expected for a 5-HT1B
autoreceptor agonist. This suggests that the local action
of CP-94,253 on 5-HT1B receptors in nerve endings is
independent on its simultaneous effect in the cell body areas
(increased 5-HT ef¯ux in the MnR and no change in the
DR). Furthermore, the CP-94,253-induced decrease in 5-HT
observed in the dorsal hippocampus, a region that receives
serotonergic innervation predominantly from the MnR
(Azmitia and Segal 1978), is clearly dissociated from an
increased ®ring rate and 5-HT release in the MnR.
Therefore, it appears that the activation of the terminal
autoreceptor overcomes opposing changes in the electro-
physiological activity of these 5-HT neurons.
In summary, 5-HT1B receptors appear to control 5-HT cell
®ring and release in rostral raphe nuclei although these
effects are more conspicuous in the MnR compared to
the DR. The activation of 5-HT1B autoreceptors (possibly
located on 5-HT nerve endings and/or varicosities within
DR and MnR) leads to a reduced release of 5-HT. On the
other hand, the effects of higher amounts of 5-HT1B receptor
agonists seems more compatible with the activation of
5-HT1B heteroreceptors located in inhibitory neurons.
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